Development and Validation of Alternative Metabolic Systems for Mutagenicity Testing in Short-Term Assays

We present here the results obtained within the framework of an EU funded project aimed to develop and validate alternative metabolic activating systems to be used in short-term mutagenicity assays, in order to reduce the use of laboratory animals for toxicology testing. The activating systems studied were established cell lines, genetically engineered V79 cell lines expressing specific rat cytochromes P450, crythrocyte-derived systems, CYP-mimetic chemical systems and plant homogenates. The metabolically competent cell lines were used as indicator cells for genotoxic effect as well as for the preparation of external activating systems using other indicator cells. The following endpoints were used:micronuclei, chromosomal aberrations and sister chromatid exchanges, mutations at the hprt locus, gene mutations in bacteria (Ames test) unscheduled DNA synthesis and DNA breaks detected in the comet assay. All metabolic systems employed activated some promutagens. With some of them, promutagens belonging to many different classes of chemicals were activated to genotoxicants, including carcinogens negative in liver S9-mediated assay. In other cases, the use of the activating systems allowed the detection of mutagens at nuch lower substrate concentrations than in liver S9-mediated assay. Therefore, the alternative metabolizing systems, which do not require the use of laboratory animals, have a substantial potential in in vitro toxicology, in the basic genotoxicity testing as well as in the clucidation of activation mechanisms. However, since the data basis is much smaller for the new systems than for the activating systems produced from subcellular liver preparations, the overlapping use of both systems is recommended for the present and near future. For example, liver S9 preparations may be used with some indicator systems (e.g. bacterial mutagenicity), and metabolically competent mammalian cell lines may be used with other indicators systems (e.g. cytogenetic endpoint) in a battery of basic tests.

RUEFF J.;  CHIAPELLA C.;  CHIPMAN J.K.;  DARROUDI F.;  DUARTE SILVA I.;  DUVERGER-VAN BOGAERT M.;  FONTI E.;  ISERN P.;  LAIRES A.;  LEONARD A.;  LLAGOSTERA M.;  MOSSESSO P.;  NATARAJAN A.T.;  PALITTI F.;  SCHINOPPI A.;  TURCHI Gino;  WERLE-SCHNEIDER G.; 

1996-11-05

JRC14048